Exploring Progenitor Cell Therapy for Ischemic Stroke Treatment

Time Sensitivity of Ischemic Stroke Treatments

Current treatments for ischemic stroke are critically time-sensitive, requiring resources and expertise typically found only at major stroke centers. Patients experiencing strokes must act quickly, as delays in seeking medical assistance can lead to cell death and permanent deficits. Presently, intravenous tissue plasminogen activator and endovascular thrombectomies are effective methods for restoring blood flow and minimizing stroke damage. However, these treatments must be administered within six hours of symptom onset, making them impractical for patients located in less populated areas due to their resource-intensive nature.

Promise of Cell Therapy in Stroke Recovery

Research has indicated that cell therapy may offer a viable solution for treating ischemic stroke. Animal studies have shown that progenitor cell therapy can limit cell damage and enhance recovery when administered beyond the typical treatment window. One particularly promising approach involves using adult multipotent progenitor cells, which are isolated from bone marrow. These cells possess distinct phenotypes and the capability for long-term culture growth. Notably, adult progenitor cells are universal; the donor and recipient do not need to be genetically matched, increasing their availability for treatment.

Study on Adult Multipotent Progenitor Cells

A recent study published in The Lancet by Hess et al. investigated the safety and efficacy of adult multipotent progenitor cells in treating ischemic stroke. The researchers aimed to determine the maximum safe and well-tolerated dosage of these cells and assess their effectiveness. Eligible participants included patients who had suffered a moderately severe ischemic stroke within the previous 48 hours. The study initially divided patients into two groups receiving different doses of progenitor cells or placebo. A third group was subsequently added, receiving the highest tolerated dosage of progenitor cells.

Patient Assessments and Outcomes

Patient evaluations were conducted at various intervals: days 7, 30, 90, and 365 following treatment. Additionally, MRIs were performed before treatment, at 30 days post-treatment, and one year later. Blood tests measuring inflammatory biomarkers were taken before treatment and at two days, one week, and one month post-treatment. The primary outcomes focused on improvements in neurological deficits and daily functioning.

Results and Implications

The findings revealed that adult multipotent progenitor cells were well tolerated, even at the highest dose of 1,200 million cells. No infusion reactions or toxic effects were reported, and adverse effects were comparable across both groups. Although no significant improvements were noted for patients receiving progenitor cells compared to those given placebo, beneficial clinical effects were observed one year after treatment. This may be attributed to the mode of administration, as intravenously infused progenitor cells may struggle to penetrate the brain. Consequently, the treatment’s benefits likely stem from immune system modulation and a reduction in neuroinflammatory mediators, which promote brain recovery.

Study Limitations and Future Research

The study faced limitations due to a small sample size, which led to an extension of the treatment inclusion window from 36 to 48 hours. Future research should aim for a narrower time frame for treatment, potentially yielding greater efficacy in stroke recovery.

Conclusion

The exploration of progenitor cell therapy presents a promising avenue for ischemic stroke treatment, particularly given its potential for broader accessibility and longer treatment windows. Continued research will be essential to fully understand its benefits and practical application in clinical settings.

Written By: Wesley Tin, BMSc